Locksmith Bio
Entrepreneur First '24Dover, US · Founded 2024 · Delaware corporation · 2 known investors
Locksmith Bio applies physics-based AI models to characterise intrinsically disordered regions of proteins and identify potential binding sites within them. Its output is intended for biopharma research teams working on early-stage discovery programmes against targets that conventional approaches have not addressed.
Also known as Locksmith Bio Inc
Founders & leadership
Locksmith Bio was founded in 2024 by Ajitesh Lunge and Yashas Devasurmutt.
Investors · 2
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 1 of 2 rounds · 2026
▶$1.9MraisedMay 2026 · 2 investors · Other TechnologyRule 506(b)
- AJITESH LUNGEExecutive Officer
- YASHAS RAMESH DEVASURMUTTDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- Minimum investment
- $400K
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Locksmith Bio is an early-stage biopharma company that applies physics-based AI models to intrinsically disordered regions of proteins in order to characterise them and locate potential binding sites. The intended output is target and binding-site information that biopharma research teams can use in early-stage discovery programmes aimed at proteins that conventional structure-based approaches have not been able to address.
Public information on the company is limited. It appears in the Entrepreneurs First portfolio directory and in a startup funding listing that categorises it under the biopharma industry with a headquarters in Dover, United States; neither source discloses employee counts, investors or product milestones.
Business model
The company positions its analytical output for use by biopharma research organisations conducting early-stage drug discovery, indicating a research-tools or discovery-partnership orientation rather than a direct-to-patient therapeutics business. Public sources do not describe contract structures, pricing or licensing terms.
Traction
The only externally reported traction signal is the $1.9M seed round captured in a Crunchbase-derived listing dated 2026-05-15 [0]. No customers, partnerships, pipeline programmes, publications or revenue figures are disclosed in the available sources.
Latest developments
The most recent verifiable datapoint is the $1.9M seed financing reflected in a Crunchbase snapshot dated 2026-05-15 [0]. The company continues to be listed in the Entrepreneurs First portfolio [1].
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Locksmith Bio is a recently founded, seed-stage company backed through the Entrepreneurs First talent investor programme, where it is listed alongside other biotechnology and pharmaceuticals portfolio companies [1]. A funding aggregator records $1.9M raised at seed stage with no lead investor named, placing the company at the earliest end of the AI-for-drug-discovery segment [0].
Technology
Physics-based artificial intelligence models are used to characterise intrinsically disordered regions of proteins — segments that lack a stable folded structure — and to identify candidate binding sites within them. No sources describe the underlying model architecture, datasets, validation results or any experimental wet-lab component.
Go-to-market
Biopharma research teams and drug discovery groups working on early-stage programmes, particularly those pursuing protein targets considered difficult to address with conventional small-molecule design approaches.
Geography
Headquarters are recorded as Dover, United States [0]. The company is listed in the portfolio of Entrepreneurs First, a talent investor operating across multiple international locations [1]; no further offices or laboratory sites are disclosed.
Risks & controversies
No controversies, litigation or regulatory issues involving the company appear in the available sources. Key risks are inherent to its stage: minimal public disclosure, a small disclosed funding base, no reported customers or validated programmes, and a computational approach to disordered protein targets whose experimental validation is not documented in any source. Several sources retrieved during research concern unrelated companies with similar names or unrelated biotech shutdown roundups and were disregarded.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsA startup funding listing citing a Crunchbase snapshot dated 2026-05-15 records a $1.9M seed round for Locksmith Bio, with no lead investor disclosed. The company is categorised under biopharma and headquartered in Dover, United States.
$1.9M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 7
primary sources listed
- Locksmith Bio raises $1.9M Seed — Startup Geekstartupgeek.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Locksmith Bio do?
- Biopharma startup using physics-based AI to map intrinsically disordered protein regions and surface new drug targets.
- Who founded Locksmith Bio?
- Locksmith Bio was founded by Ajitesh Lunge, Yashas Devasurmutt in 2024.
- Who are Locksmith Bio's investors?
- Locksmith Bio's investors include Entrepreneur First, Transpose Platform Management.
- How much funding has Locksmith Bio raised?
- Locksmith Bio has disclosed $1.9M raised across 1 of its 2 known rounds.
- Where is Locksmith Bio headquartered?
- Locksmith Bio is headquartered in Dover, US.